Citius Oncology (CTOR) said Tuesday that it has nearly completed preparations for the commercial launch of Lymphir to treat relapsed or refractory cutaneous T-cell lymphoma.
The company said it has completed commercial-scale manufacturing of Lymphir, with enough to meet projected demand for 12 to 18 months after the product launches.
The company said it expects to roll out Lymphir beginning in H2.
Price: 1.32, Change: -0.07, Percent Change: -5.04
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.